Kashefi Babak, Mohammadi Mehdi, Rezaei Farzin, Ghadami Narges, Jalili Khashaiar, Jalili Ali
Neurosciences Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Neuropsychiatr Dis Treat. 2020 Apr 5;16:909-914. doi: 10.2147/NDT.S234013. eCollection 2020.
Electroconvulsive therapy (ECT) is a non-pharmacological method for the treatment of psychiatric disorders. The precise biochemical mechanism of the effects of ECT is not clear, and since the two factors including matrix metalloproteinase-9 (MMP-9) and stromal cell-derived factor-1 alpha (CXCL12) play an important role in improving nerve damage, the effects of ECT and its relation with serum levels of MMP-9 and CXCL12 in patients with mania were investigated in this study.
In this before and after intervention study, the patients with mania, referring to the Qods Hospital in Sanandaj, were selected by the census method during the years 2015-2018. Young's test was performed 24 hrs before and after the first, third, and sixth sessions of ECT. For biochemical analysis, 3 mL of peripheral blood were taken prior to any anesthesia and 6 hrs after the first, third, and sixth sessions. Data were analyzed by two-way ANOVA and Pearson correlation coefficient by using the SPSS16 software.
The results showed a significant decrease in Young's test scores during the first to the sixth session of ECT (P≤0.05). Although the levels of CXCL12 were slightly increased after the sixth course of ECT, they were not significant. Moreover, there were no significant relationship between the Young's test score and the serum levels of both MMP-9 and CXCL12 (P≥0.05).
ECT improved patients clinically, but this effect was independent of serum levels of MMP-9 and CXCL12, and possibly other biochemical factors are involved in this pathway.
电休克疗法(ECT)是一种治疗精神疾病的非药物方法。ECT作用的确切生化机制尚不清楚,由于基质金属蛋白酶-9(MMP-9)和基质细胞衍生因子-1α(CXCL12)这两个因素在改善神经损伤中起重要作用,本研究调查了ECT对躁狂症患者的影响及其与血清MMP-9和CXCL12水平的关系。
在这项干预前后研究中,2015年至2018年期间,采用普查法选取了转诊至萨南达杰圣城医院的躁狂症患者。在ECT的第一次、第三次和第六次治疗前24小时以及治疗后进行杨氏测试。为进行生化分析,在任何麻醉前采集3 mL外周血,并在第一次、第三次和第六次治疗后6小时采集血样。使用SPSS16软件通过双向方差分析和Pearson相关系数对数据进行分析。
结果显示,在ECT的第一次至第六次治疗期间,杨氏测试评分显著降低(P≤0.05)。尽管在第六个疗程的ECT后CXCL12水平略有升高,但差异不显著。此外,杨氏测试评分与MMP-9和CXCL12的血清水平之间均无显著相关性(P≥0.05)。
ECT在临床上改善了患者的症状,但这种效果独立于血清MMP-9和CXCL12水平,可能该途径涉及其他生化因素。